Clinical trials: Severe Respiratory Distress
COVID-19 Acute Respiratory Distress Syndrome, Respiratory Distress Syndrome
Safety and Effectiveness of Placental Derived Exosomes and Umbilical Cord Mesenchymal Stem Cells in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) Associated With the Novel Corona Virus Infection (COVID-19)
Recent advances have been made in prevention of the viral infection via vaccines but there is still need for effective treatment options for patients. Novel therapies need to be developed to further improve clinical outcomes.
- Trial name
- NCT05387278
- Testing
- EV-Pure™ and WJ-Pure™
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Vitti Labs, LLC
Acute Respiratory Distress Syndrom
Selective Lung Recruitment in Moderate to Severe ARDS : a Pilot Study
Acute respiratory distress syndrome (ARDS) is an acute condition affecting the lung after clinical aggression ( infectious process, pancreatitis, acute inflammatory event).
- Trial name
- SRIMSA (NCT06609629)
- Testing
- Selective lung recruitment
- Volunteers
- 10 people
- Sponsor
- University Hospital, Caen
Respiratory Distress Syndrome, Adult, COVID-19
Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19
Single blind randomized clinical trial designed to evaluate the efficacy of the combination of hydroxychloroquine and dexamethasone as treatment for severe Acute Respiratory Distress Syndrome (ARDS) related to coronavirus disease…
- Trial name
- DHYSCO (NCT04347980)
- Testing
- Dexamethasone and Hydroxychloroquine, Hydroxychloroquine
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Centre Chirurgical Marie Lannelongue
Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum
Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)
This Phase 2 study tests whether adding two immune therapies - nogapendekin alfa-inbakicept (NAI) and off-the-shelf iNKT cell infusions - to standard care can safely help critically ill adults with severe community-acquired…
- Conditions
- Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum, Sepsis, Lymphopenia / Immunoparalysis in Critically Ill Adults
- Trial name
- NCT07492888
- Testing
- Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797)
- Sponsor
- ImmunityBio, Inc.
Severe Acute Respiratory Distress Syndrome, Refractory Hypoxemia
ECMO for Critically Ill Patients With Respiratory Failure and/or Circulatory Failure
Extracorporeal membrane oxygenation (ECMO) had been used to treat refractory hypoxemia associated with acute respiratory distress syndrome (ARDS).
- Trial name
- NCT04031794
- Testing
- Extra Corporeal Membrane Oxygenator (ECMO)
- Where
- Thailand
- Volunteers
- 250 people
- Sponsor
- Mahidol University
Coma, Major Trauma
Succinylcholine vs Rocuronium for Prehospital Emergency Intubation
All adult patients with spontaneous cardiac activity and requiring tracheal intubation in the pre hospital emergency context will be included in order to compare the use of succinylcholine vs Rocuronium for prehospital emergency…
- Conditions
- Coma, Major Trauma, Respiratory Distress, Shock
- Trial name
- CURASMUR (NCT02000674)
- Testing
- Succinylcholine : 1mg/kg, Rocuronium : 1.2 mg/kg
- Where
- 17 sites in France
- Volunteers
- 1,321 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Severe Acute Respiratory Syndrome (SARS) Pneumonia, Coronavirus Infections
Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome
COVID-19 infection is overwhelming Italian healthcare. There is an urgent need for a solution to the lack of ICU beds and increasing deaths day after day.
- Conditions
- Severe Acute Respiratory Syndrome (SARS) Pneumonia, Coronavirus Infections, ARDS, Human
- Trial name
- MP-C19 (NCT04323592)
- Testing
- Methylprednisolone, standard care
- Where
- Italy
- Volunteers
- 173 people
- Sponsor
- University of Trieste
Covid-19, Respiratory Distress Syndrome
Vitamin D Supplementation and Clinical Outcomes in Severe COVID-19 Patients
Single center, open label randomized clinical trial. Study location: tertiary hospital center (University Hospital Split, Croatia).
- Conditions
- Covid-19, Respiratory Distress Syndrome, Vitamin D Deficiency
- Trial name
- NCT05384574
- Testing
- cholecalciferol
- Where
- Croatia
- Volunteers
- 200 people
- Sponsor
- University Hospital of Split
Dyspnea, COVID-19
Two-year Efficacy of Three Exercise Rehabilitation Strategies on Dyspnea in Patients Who Presented With Secondary Respiratory Distress Syndrome Secondary to Severe COVID-19 Pneumonia
Dyspnea is defined by a subjective sensation of respiratory discomfort, the intensity of which varies according to the terrain, the anamnesis and the cause.
- Trial name
- RECOVER_FU (NCT05890560)
- Where
- 4 sites in France
- Volunteers
- 120 people
- Sponsor
- Fondation Hôpital Saint-Joseph
ARDS, Human
Effect of Electric Impedance Tomography-Guided PEEP Titration
Acute respiratory syndrome distress (ARDS) is a clinical common syndrome with high mortality. Mechanical ventilation (MV) is the cornerstone of management of ARDS but can lead to ventilator-induced lung injury.
- Trial name
- NCT05736185
- Testing
- PEEP selection
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Southeast University, China
Sepsis, Pneumonia
Benefit of Clarithromycin in Patients With Severe Infections Through Modulation of the Immune System
High mortality associated with sepsis and Multiple Organ Dysfunction Syndrome (MODS) calls for alternative, individualized therapies in selected patients that might benefit form specific interventions.
- Conditions
- Sepsis, Pneumonia, Gram-Negative Bacteria Infection, Multiple Organ Failure
- Trial name
- INCLASS (NCT03345992)
- Testing
- Clarithromycin, Water for injection
- Where
- 12 sites in Belgium, Greece
- Volunteers
- 110 people
- Sponsor
- Hellenic Institute for the Study of Sepsis
Acute Respiratory Distress Syndrome, Chest Trauma
Serum sRAGE, CC16, and Syndecan-1 as Predictors of ARDS and Mortality After Severe Chest Trauma
This prospective cohort study aims to evaluate whether blood levels of soluble receptor for advanced glycation end products (sRAGE), Club Cell Protein-16 (CC16), and Syndecan-1 measured early after severe chest trauma can predict…
- Trial name
- NCT07774338
- Testing
- No intervention - observational study
- Volunteers
- 85 people
- Sponsor
- Assiut University
Acute Respiratory Distress Syndrome
Effectiveness of Convalescent Immune Plasma Therapy
The aim of the study is to evaluate the safety, improvement of clinical symptoms and laboratory parameters of convalescent immune plasma treatment in severe Covid-19 patients with ARDS.
- Trial name
- NCT04442958
- Testing
- Convalescent Immune Plasma
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Bagcilar Training and Research Hospital
Covid19, Acute Respiratory Distress Syndrome
Clinical Features of COVID-19 Patients
The data were retrospectively collected during the first and the second wave of epidemic in COVID-19 patients with Severe Acute Respiratory Syndrome Coronavirus 2, at the moment of intensive care unit admission and during the in…
- Conditions
- Covid19, Acute Respiratory Distress Syndrome, Ventilatory Failure
- Trial name
- NCT04815304
- Testing
- peripheral lymphocytes subsets
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- San Salvatore Hospital of L'Aquila
ARDS, Human, Extracorporeal Membrane Oxygenation
Use of Prone Position Ventilation in Danish Patients With COVID-19 Induced Severe ARDS Treated With VV-ECMO
Prone position ventilation was used 220 times in 44 out of 68 patients with severe COVID-19 induced ARDS treated with VV-ECMO. PPV treated patients did not benefit from PPV and the incidence of PPV related adverse events was high
- Conditions
- ARDS, Human, Extracorporeal Membrane Oxygenation, COVID-19 Acute Respiratory Distress Syndrome, Prone Position
- Trial name
- NCT05693051
- Testing
- Prone position ventilation
- Where
- 2 sites in Denmark
- Volunteers
- 68 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
COVID19 ARDS
Efficacy of Infusions of MSC From Wharton Jelly in the SARS-Cov-2 (COVID-19) Related Acute Respiratory Distress Syndrome
Mesenchymal stem cells (MSCs) are of potential help in acute respiratory distress syndrome (ARDS), due to their anti-inflammatory properties.
- Trial name
- MSC-COVID19 (NCT04625738)
- Testing
- Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Central Hospital, Nancy, France
Pediatric Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
Prone Position During ECMO in Pediatric Patients With Severe ARDS
In 2023, the second Pediatric Acute Lung Injury Consensus Conference (PALICC-2) updated the diagnostic and management guidelines for Pediatric Acute Respiratory Distress Syndrome (PARDS).
- Trial name
- PEPAD (NCT06369584)
- Testing
- prone position
- Where
- 8 sites in China
- Volunteers
- 7 people
- Sponsor
- Seventh Medical Center of PLA General Hospital
Acute Respiratory Distress Syndrome
Artificial Increase in Chest Wall Elastance as an Alternative to Prone Positioning in Moderate-to-severe ARDS.
During moderate to severe ARDS, sessions of prone positioning lead to lung and chest wall mechanics changes that modify regional ventilation, with a final redistribution of tidal volume and PEEP towards dependent lung regions…
- Trial name
- ALTERPRONE (NCT03719937)
- Testing
- weight on the anterior chest of the patient
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Catholic University of the Sacred Heart
Covid19
Early Cognitive Assessment and Evolutionary Monitoring of Patients With Severe ARDS on COVID-19 Pneumonia Requiring Mechanical Ventilation
The new coronavirus pandemic responsible for the severe acute respiratory syndrome SARS-CoV2 requires, in its severe forms, the use of invasive ventilation in intensive care.
- Trial name
- CognitiVID (NCT04468035)
- Where
- France
- Volunteers
- 22 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Severe Acute Respiratory Syndrome Coronavirus 2, Acute Respiratory Distress Syndrome
Pulmonary Fibrosis During Severe COVID-19 Pneumonia
The COVID-19 pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS CoV-2), an emerging coronavirus, which has already infected 192 million people with a case fatality rate close to 2%.
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2, Acute Respiratory Distress Syndrome, Pulmonary Fibrosis
- Trial name
- FIBRO-COVID (NCT04987528)
- Testing
- Aminoterminal type III peptide of procollagen, Lung computed tomography
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Hôpital Européen Marseille